- SRA737 Monotherapy trial prioritized for ovarian cancer; targeting enrollment of 65 patients with preliminary data anticipated in H1 2019 - - SRA737 LDG Combination trial to be amended and...
Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with...
View all news releases
Next Generation DDR Therapeutics - Q3 2018
View All Presentations
Location: New York, New York
View all events and webcasts
James Smith, Vice President Corporate Affairs
Sign up for investor alerts